

Hani Al-Salami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7204768/publications.pdf>

Version: 2024-02-01

160
papers

4,414
citations

101543

36
h-index

149698

56
g-index

162
all docs

162
docs citations

162
times ranked

3756
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of Bile Acids in Hydrogel Pharmaceutical Formulations on Dissolution Rate and Permeation of Clindamycin Hydrochloride. <i>Gels</i> , 2022, 8, 35.	4.5	4
2	Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 836.	4.1	5
3	Single-Cellular Biological Effects of Cholesterol-Catabolic Bile Acid-Based Nano/Micro Capsules as Anti-Inflammatory Cell Protective Systems. <i>Biomolecules</i> , 2022, 12, 73.	4.0	8
4	Taurine Grafted Micro-Implants Improved Functions without Direct Dependency between Interleukin-6 and the Bile Acid Lithocholic Acid in Plasma. <i>Biomedicines</i> , 2022, 10, 111.	3.2	3
5	Evaluation of the water-holding and anti-spoilage effect of a bacterial cellulose nanocrystal coating for the storage of vacuum-packaged beef. <i>Food Packaging and Shelf Life</i> , 2022, 31, 100818.	7.5	8
6	Pharmacological Dose-Effect Profiles of Various Concentrations of Humanised Primary Bile Acid in Encapsulated Cells. <i>Nanomaterials</i> , 2022, 12, 647.	4.1	4
7	Gut Microbiota Metabolism of Azathioprine: A New Hallmark for Personalized Drug-Targeted Therapy of Chronic Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, 879170.	3.5	7
8	The emerging role of bile acids as critical components in nanotechnology and bioengineering: Pharmacology, formulation optimizers and hydrogel-biomaterial applications. <i>Biomaterials</i> , 2022, 283, 121459.	11.4	22
9	The Effect of Deoxycholic Acid on Chitosan-Enabled Matrices for Tissue Scaffolding and Injectable Nanogels. <i>Gels</i> , 2022, 8, 358.	4.5	8
10	Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study. <i>Biomolecules</i> , 2022, 12, 877.	4.0	2
11	'In vitro' assessments of microencapsulated viable cells as a result of primary bile acid-encapsulated formulation for inflammatory disorders. <i>Scripta Medica</i> , 2022, 53, 103-115.	0.1	1
12	Comparative evaluation of encapsulation using β -cyclodextrin versus freeze-drying for better retention and stabilizing of black Périgord truffle (<i>Tuber melanosporum</i>) aroma. <i>Journal of Food Science</i> , 2022, 87, 3482-3495.	3.1	4
13	Antimicrobial efficacy of nisin-loaded bacterial cellulose nanocrystals against selected meat spoilage lactic acid bacteria. <i>Carbohydrate Polymers</i> , 2021, 251, 117096.	10.2	50
14	Cutting-edge biotechnological advancement in islet delivery using pancreatic and cellular approaches. <i>Future Science OA</i> , 2021, 7, FSO660.	1.9	3
15	PAMPA model of gliclazide permeability: The impact of probiotic bacteria and bile acids. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 158, 105668.	4.0	15
16	Fabrication techniques for the preparation of orally administered insulin nanoparticles. <i>Journal of Drug Targeting</i> , 2021, 29, 365-386.	4.4	6
17	A novel biocompatible polymeric blend for applications requiring high toughness and tailored degradation rate. <i>Journal of Materials Chemistry B</i> , 2021, 9, 2532-2546.	5.8	15
18	β -Cyclodextrin-containing chitosan-oligonucleotide nanoparticles improve insulin bioactivity, gut cellular permeation and glucose consumption. <i>Journal of Pharmacy and Pharmacology</i> , 2021, 73, 726-739.	2.4	7

#	ARTICLE	IF	CITATIONS
19	Effectiveness of gelatine and chitosan spray coating for extending shelf life of vacuum-packaged beef. <i>International Journal of Food Science and Technology</i> , 2021, 56, 4026-4037.	2.7	14
20	Bile acids as novel enhancers of CNS targeting antitumor drugs: a comprehensive review. <i>Pharmaceutical Development and Technology</i> , 2021, 26, 617-633.	2.4	7
21	3,5-Dibromophenyl-functionalised imidazolium salts and their corresponding [Au(NHC) ₂] ⁺ complexes: synthesis, supramolecular chemistry and anti-cancer activity. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2021, 101, 227-242.	1.6	2
22	Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid. <i>PLoS ONE</i> , 2021, 16, e0243858.	2.5	6
23	A Functionalized Paper Strip-Based Platform for Rapid Detection of Anticancer Drug Concentrations. <i>Journal of Sensors</i> , 2021, 2021, 1-11.	1.1	0
24	Enhanced Bilosomal Properties Resulted in Optimum Pharmacological Effects by Increased Acidification Pathways. <i>Pharmaceutics</i> , 2021, 13, 1184.	4.5	12
25	Advancements in Assessments of Bio-Tissue Engineering and Viable Cell Delivery Matrices Using Bile Acid-Based Pharmacological Biotechnologies. <i>Nanomaterials</i> , 2021, 11, 1861.	4.1	14
26	A Review on Recent Advancement on Age-Related Hearing Loss: The Applications of Nanotechnology, Drug Pharmacology, and Biotechnology. <i>Pharmaceutics</i> , 2021, 13, 1041.	4.5	17
27	Physicochemical characterisation of kafirins extracted from sorghum grain and dried distillers grain with solubles related to their biomaterial functionality. <i>Scientific Reports</i> , 2021, 11, 15204.	3.3	5
28	Pharmacological and Biological Study of Microencapsulated ProbucoL-Secondary Bile Acid in a Diseased Mouse Model. <i>Pharmaceutics</i> , 2021, 13, 1223.	4.5	13
29	ProbucoL Pharmacological and Bio-Nanotechnological Effects on Surgically Transplanted Graft Due to Powerful Anti-Inflammatory, Anti-Fibrotic and Potential Bile Acid Modulatory Actions. <i>Pharmaceutics</i> , 2021, 13, 1304.	4.5	7
30	Cognitive Deficits in Type-1 Diabetes: Aspects of Glucose, Cerebrovascular and Amyloid Involvement. <i>Pharmaceutical Research</i> , 2021, 38, 1477-1484.	3.5	3
31	Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study. <i>Cells</i> , 2021, 10, 2437.	4.1	8
32	The increasing role of pigment epithelium-derived factor in metastasis: from biological importance to a promising target. <i>Biochemical Pharmacology</i> , 2021, 193, 114787.	4.4	11
33	The Effects of Primary Unconjugated Bile Acids on Nanoencapsulated Pharmaceutical Formulation of Hydrophilic Drugs: Pharmacological Implications. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 4423-4434.	4.3	11
34	Polyelectrolytes Formulated with Primary Unconjugated Bile Acid Optimised Pharmacology of Bio-Engineered Implant. <i>Pharmaceutics</i> , 2021, 13, 1713.	4.5	5
35	Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, , 1.	1.6	1
36	The Effects of Accelerated Temperature-Controlled Stability Systems on the Release Profile of Primary Bile Acid-Based Delivery Microcapsules. <i>Pharmaceutics</i> , 2021, 13, 1667.	4.5	8

#	ARTICLE	IF	CITATIONS
37	Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices. <i>Therapeutic Delivery</i> , 2021, 12, 723-737.	2.2	6
38	Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. <i>Scientific Reports</i> , 2021, 11, 22123.	3.3	2
39	Artificial Cell Encapsulation for Biomaterials and Tissue Bio-Nanoengineering: History, Achievements, Limitations, and Future Work for Potential Clinical Applications and Transplantation. <i>Journal of Functional Biomaterials</i> , 2021, 12, 68.	4.4	9
40	Pharmaceutical formulation and polymer chemistry for cell encapsulation applied to the creation of a lab-on-a-chip bio-microsystem. <i>Therapeutic Delivery</i> , 2021, , .	2.2	5
41	Bile acid permeation enhancement for inner ear cochlear drug pharmacological uptake: bio-nanotechnologies in chemotherapy-induced hearing loss. <i>Therapeutic Delivery</i> , 2021, 12, 807-819.	2.2	7
42	DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 1-14.	1.6	13
43	Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. <i>Scientific Reports</i> , 2020, 10, 106.	3.3	41
44	A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 165-171.	2.7	17
45	Role of metformin in various pathologies: state-of-the-art microcapsules for improving its pharmacokinetics. <i>Therapeutic Delivery</i> , 2020, 11, 733-753.	2.2	6
46	Polydimethylsiloxane-customized nanoplatform for delivery of antidiabetic drugs. <i>Therapeutic Delivery</i> , 2020, 11, 415-429.	2.2	3
47	Applications of superparamagnetic iron oxide nanoparticles in drug and therapeutic delivery, and biotechnological advancements. <i>Beilstein Journal of Nanotechnology</i> , 2020, 11, 1092-1109.	2.8	52
48	Pharmacological and Advanced Cell Respiration Effects, Enhanced by Toxic Human-Bile Nano-Pharmaceuticals of Probucol Cell-Targeting Formulations. <i>Pharmaceutics</i> , 2020, 12, 708.	4.5	25
49	C2C12 cell model: its role in understanding of insulin resistance at the molecular level and pharmaceutical development at the preclinical stage. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 1667-1693.	2.4	53
50	A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism. <i>Developmental Neuroscience</i> , 2020, 42, 12-48.	2.0	76
51	Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies. <i>Scientific Reports</i> , 2020, 10, 7715.	3.3	30
52	Histological effects of pharmacologically active human bile acid nano/micro-particles in Type-1 diabetes. <i>Therapeutic Delivery</i> , 2020, 11, 157-171.	2.2	9
53	Impedance Spectroscopic Analysis of the Interdigitated Flexible Sensor for Bacteria Detection. <i>IEEE Sensors Journal</i> , 2020, 20, 12791-12798.	4.7	12
54	Advanced and multifaceted stability profiling of the first-line antidiabetic drugs metformin, gliclazide and glipizide under various controlled stress conditions. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 362-368.	2.7	10

#	ARTICLE	IF	CITATIONS
55	Lyophilisation Improves Bioactivity and Stability of Insulin-Loaded Polymeric-Oligonucleotide Nanoparticles for Diabetes Treatment. <i>AAPS PharmSciTech</i> , 2020, 21, 108.	3.3	24
56	Development of orally administered insulin-loaded polymeric-oligonucleotide nanoparticles: statistical optimization and physicochemical characterization. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 1238-1252.	2.0	12
57	Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1361-1376.	5.0	31
58	Effectiveness of bacterial cellulose in controlling purge accumulation and improving physicochemical, microbiological, and sensorial properties of vacuum-packaged beef. <i>Journal of Food Science</i> , 2020, 85, 2153-2163.	3.1	13
59	Cellular assays and applied technologies for characterisation of orally administered protein nanoparticles: a systematic review. <i>Journal of Drug Targeting</i> , 2020, 28, 585-599.	4.4	14
60	Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation. <i>Pharmacological Reports</i> , 2020, 72, 368-378.	3.3	16
61	<p>Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, inÂPancreatic Î²-Cells</p>. <i>Nanotechnology, Science and Applications</i> , 2020, Volume 13, 1-9.	4.6	13
62	Formulation and characterisation of insulin-loaded chitosan nanoparticles capable of inducing glucose uptake in skeletal muscle cells in vitro. <i>Journal of Drug Delivery Science and Technology</i> , 2020, 57, 101738.	3.0	27
63	Current status and applications of animal models in pre-clinical development of orally administered insulin-loaded nanoparticles. <i>Journal of Drug Targeting</i> , 2020, 28, 882-903.	4.4	12
64	Modulatory Nano/Micro Effects of Diabetes Development on Pharmacology of Primary and Secondary Bile Acids Concentrations. <i>Current Diabetes Reviews</i> , 2020, 16, 900-909.	1.3	14
65	Pharmacological effects of secondary bile acid microparticles in diabetic murine model. <i>Current Diabetes Reviews</i> , 2020, 16, .	1.3	9
66	Microencapsulation of Coenzyme Q10 and bile acids using ionic gelation vibrational jet flow technology for oral delivery. <i>Therapeutic Delivery</i> , 2020, 11, 791-805.	2.2	11
67	Pharmacokinetic and drug absorption profiles of the anti-hyperglycaemic agent gliclazide in oral tissue-targeted microcapsules in rats. <i>Scripta Medica</i> , 2020, 51, 15-20.	0.1	5
68	Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide. <i>Journal of Food and Drug Analysis</i> , 2019, 27, 315-322.	1.9	47
69	Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. <i>Pharmacological Research</i> , 2019, 146, 104333.	7.1	27
70	Transport and Biotransformation of Gliclazide and the Effect of Deoxycholic Acid in a Probiotic Bacteria Model. <i>Frontiers in Pharmacology</i> , 2019, 10, 1083.	3.5	8
71	Bile acid-polymer-probucol microparticles: protective effect on pancreatic Î²-cells and decrease in type 1 diabetes development in a murine model. <i>Pharmaceutical Development and Technology</i> , 2019, 24, 1272-1277.	2.4	11
72	Environmental Transformation of Pharmaceutical Formulations: A Scientific Review. <i>Archives of Environmental Contamination and Toxicology</i> , 2019, 77, 155-161.	4.1	18

#	ARTICLE	IF	CITATIONS
73	An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques. PLoS ONE, 2019, 14, e0214984.	2.5	12
74	Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment. Therapeutic Delivery, 2019, 10, 99-106.	2.2	19
75	Bio-nanotechnological advancement of orally administered insulin nanoparticles: Comprehensive review of experimental design for physicochemical characterization. International Journal of Pharmaceutics, 2019, 572, 118720.	5.2	23
76	Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Therapeutic Delivery, 2019, 10, 563-571.	2.2	12
77	Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids. Therapeutic Delivery, 2019, 10, 573-583.	2.2	12
78	Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diabetes and Vascular Disease Research, 2019, 16, 87-97.	2.0	44
79	Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids. Pharmacological Research, 2019, 141, 291-297.	7.1	26
80	Testing and Characterization of Different Papers as Substrate Material for Printed Electronics and Application in Humidity Sensor. Sensors and Materials, 2019, 31, 2981.	0.5	11
81	Influence of the Main Filter on QRS-amplitude and Duration in Human Electrocardiogram. Measurement Science Review, 2019, 19, 29-34.	1.0	3
82	Influence of Biotechnological Processes, Speed of Formulation Flow and Cellular Concurrent Stream-Integration on Insulin Production from β -cells as a Result of Co-Encapsulation with a Highly Lipophilic Bile Acid. Cellular and Molecular Bioengineering, 2018, 11, 65-75.	2.1	18
83	Microparticles, microcapsules and microspheres: A review of recent developments and prospects for oral delivery of insulin. International Journal of Pharmaceutics, 2018, 537, 223-244.	5.2	206
84	The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Delivery and Translational Research, 2018, 8, 543-551.	5.8	42
85	The effect of molecular weights of microencapsulating polymers on viability of mouse-cloned pancreatic β -cells: biomaterials, osmotic forces and potential applications in diabetes treatment. Pharmaceutical Development and Technology, 2018, 23, 145-150.	2.4	18
86	The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation. Journal of Drug Targeting, 2018, 26, 551-562.	4.4	47
87	Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 269-280.	1.6	23
88	Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic β -cells cultured in high ratio poly-L-ornithine-gel hydrogel colloidal dispersion: applications in cell-biomaterials, tissue engineering and biotechnological applications. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 1156-1162.	2.8	27
89	Oral insulin delivery: existing barriers and current counter-strategies. Journal of Pharmacy and Pharmacology, 2018, 70, 197-213.	2.4	103
90	Eudragit [®] -based microcapsules of probucol with a gut-bacterial processed secondary bile acid. Therapeutic Delivery, 2018, 9, 811-821.	2.2	21

#	ARTICLE	IF	CITATIONS
91	Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 748-754.	2.8	28
92	Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. <i>Frontiers in Pharmacology</i> , 2018, 9, 1283.	3.5	159
93	Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. <i>Frontiers in Pharmacology</i> , 2018, 9, 1382.	3.5	78
94	Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 741-747.	2.8	22
95	Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. <i>Therapeutic Delivery</i> , 2018, 9, 703-709.	2.2	27
96	Quantification of BSA-loaded chitosan/oligonucleotide nanoparticles using reverse-phase high-performance liquid chromatography. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 6991-7006.	3.7	15
97	Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus. <i>International Journal of Pharmaceutics</i> , 2018, 549, 201-217.	5.2	80
98	Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid. <i>AAPS PharmSciTech</i> , 2018, 19, 3009-3018.	3.3	7
99	Dried blood spot: Utilizing dry blood for pharmacokinetic investigations - an old method with great future for therapeutic drug monitoring. <i>Vojnosanitetski Pregled</i> , 2018, 75, 1222-1225.	0.2	2
100	Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2017, 125, 28-32.	1.2	25
101	Antihypertensive agents do not prevent blood-brain barrier dysfunction and cognitive deficits in dietary-induced obese mice. <i>International Journal of Obesity</i> , 2017, 41, 926-934.	3.4	23
102	Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 106, 1-9.	4.0	17
103	The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 881-890.	1.6	9
104	The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus. <i>Therapeutic Delivery</i> , 2017, 8, 401-409.	2.2	18
105	Innovative Microcapsules for Pancreatic β -Cells Harvested from Mature Double-Transgenic Mice: Cell Imaging, Viability, Induced Glucose-Stimulated Insulin Measurements and Proinflammatory Cytokines Analysis. <i>Pharmaceutical Research</i> , 2017, 34, 1217-1223.	3.5	28
106	Alginate-combined cholic acid increased insulin secretion of microencapsulated mouse cloned pancreatic β cells. <i>Therapeutic Delivery</i> , 2017, 8, 833-842.	2.2	21
107	Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. <i>Journal of Controlled Release</i> , 2017, 264, 247-275.	9.9	179
108	New Biotechnological Microencapsulating Methodology Utilizing Individualized Gradient-Screened Jet Laminar Flow Techniques for Pancreatic β -Cell Delivery: Bile Acids Support Cell Energy-Generating Mechanisms. <i>Molecular Pharmaceutics</i> , 2017, 14, 2711-2718.	4.6	20

#	ARTICLE	IF	CITATIONS
109	High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 1005-1011.	1.6	8
110	Blood-Brain Barrier Dysfunction Precedes Cognitive Decline and Neurodegeneration in Diabetic Insulin Resistant Mouse Model: An Implication for Causal Link. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 399.	3.4	108
111	Mammary Gland Pathology Subsequent to Acute Infection with Strong versus Weak Biofilm Forming <i>Staphylococcus aureus</i> Bovine Mastitis Isolates: A Pilot Study Using Non-Invasive Mouse Mastitis Model. <i>PLoS ONE</i> , 2017, 12, e0170668.	2.5	30
112	Advanced bile acid-based multi-compartmental microencapsulated pancreatic β -cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 588-595.	2.8	45
113	Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes. <i>Journal of Diabetes</i> , 2016, 8, 238-245.	1.8	7
114	Alginate-deoxycholic Acid Interaction and Its Impact on Pancreatic β -Cells and Insulin Secretion and Potential Treatment of Type 1 Diabetes. <i>Journal of Pharmaceutical Innovation</i> , 2016, 11, 156-161.	2.4	21
115	Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine β -cell Survival and the Inflammatory Response. <i>BioNanoScience</i> , 2016, 6, 103-109.	3.5	32
116	Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-microcapsules of β -cells. <i>Therapeutic Delivery</i> , 2016, 7, 171-178.	2.2	32
117	The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes. <i>Journal of Microencapsulation</i> , 2016, 33, 569-574.	2.8	22
118	The Effect of Diabetes and Hypertension on the Placental Permeation of the Hydrophilic Drug, Ranitidine. <i>Placenta</i> , 2016, 48, 144-150.	1.5	4
119	Viability and topographical analysis of microencapsulated β -cells exposed to a biotransformed tertiary bile acid: an ex vivo study. <i>International Journal of Nano and Biomaterials</i> , 2016, 6, 74.	0.1	28
120	Biological Assessments of Encapsulated Pancreatic β -Cells: Their Potential Transplantation in Diabetes. <i>Cellular and Molecular Bioengineering</i> , 2016, 9, 530-537.	2.1	23
121	Designing anti-diabetic β -cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis. <i>Biotechnology Progress</i> , 2016, 32, 501-509.	2.6	43
122	Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β -cells. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 194-200.	2.8	50
123	The Influence of Stabilized Deconjugated Ursodeoxycholic Acid on Polymer-Hydrogel System of Transplantable NIT-1 Cells. <i>Pharmaceutical Research</i> , 2016, 33, 1182-1190.	3.5	34
124	The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable β -cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies. <i>Drug Delivery and Translational Research</i> , 2016, 6, 17-23.	5.8	35
125	A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes. <i>Drug Delivery</i> , 2016, 23, 2869-2880.	5.7	29
126	Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β -cell line. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 1642-1653.	2.8	47

#	ARTICLE	IF	CITATIONS
127	The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 1508-1519.	2.8	26
128	Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2016, 44, 1290-1297.	2.8	49
129	The Effects of Ionic Gelation- Vibrational Jet Flow Technique in Fabrication of Microcapsules Incorporating β -cell: Applications in Diabetes. <i>Current Diabetes Reviews</i> , 2016, 13, 91-96.	1.3	33
130	Typing of <i>Staphylococcus aureus</i> isolated from bovine mastitis cases in Australia and India. <i>Australian Veterinary Journal</i> , 2015, 93, 278-282.	1.1	10
131	Drug Permeation across the Blood-Brain Barrier: Applications of Nanotechnology. <i>British Journal of Medicine and Medical Research</i> , 2015, 6, 547-556.	0.2	17
132	Probuco Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes. <i>AAPS PharmSciTech</i> , 2015, 16, 45-52.	3.3	47
133	Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An <i>in vitro</i> study. <i>Journal of Microencapsulation</i> , 2015, 32, 589-597.	2.8	42
134	The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. <i>Drug Delivery and Translational Research</i> , 2015, 5, 511-522.	5.8	48
135	An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. <i>Pharmaceutical Development and Technology</i> , 2015, 20, 702-709.	2.4	56
136	Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. <i>Journal of Microencapsulation</i> , 2015, 32, 151-156.	2.8	38
137	Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probuco. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1221.	4.3	32
138	Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice. <i>Current Drug Delivery</i> , 2014, 11, 146-153.	1.6	17
139	Inflammatory bowel disease: clinical aspects and treatments. <i>Journal of Inflammation Research</i> , 2014, 7, 113.	3.5	321
140	Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1003.	4.3	30
141	An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic) Tj ETQq1 1 0,784314 rgBT /Overlo	4.3	27
142	Serological versus molecular typing of surface-associated immune evading polysaccharide antigens-based phenotypes of <i>Staphylococcus aureus</i> . <i>Journal of Medical Microbiology</i> , 2014, 63, 1427-1431.	1.8	3
143	Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. <i>Journal of Pharmaceutical Innovation</i> , 2014, 9, 150-157.	2.4	58
144	Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women. <i>BMC Pregnancy and Childbirth</i> , 2013, 13, 188.	2.4	6

#	ARTICLE	IF	CITATIONS
145	Screening for Antidiabetic Activities. <i>Methods in Molecular Biology</i> , 2013, 1055, 207-218.	0.9	1
146	Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat. <i>Journal of Diabetes Research</i> , 2013, 2013, 1-8.	2.3	44
147	Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2012, 37, 99-108.	1.6	41
148	Potentials and Limitations of Bile Acids and Probiotics in Diabetes Mellitus. , 2011, , .		5
149	Transit Time Affects the Community Stability of <i>Lactobacillus</i> and <i>Bifidobacterium</i> Species in an <i>In Vitro</i> Model of Human Colonic Microbiota. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 2011, 39, 351-356.	0.9	22
150	Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2009, 34, 93-99.	1.6	28
151	Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2009, 34, 43-50.	1.6	42
152	Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2008, 33, 101-106.	1.6	102
153	The influence of 3 β ,7 β -dihydroxy-12-keto-5 β -cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2008, 33, 137-142.	1.6	42
154	Probiotic Pre-treatment Reduces Gliclazide Permeation (<i>ex vivo</i>) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. <i>Archives of Drug Information</i> , 2008, 1, 35-41.	1.6	55
155	Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide <i>in vitro</i> in healthy and diabetic rats treated with probiotics. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , 2008, 30, 107.	0.8	60
156	Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. <i>Pharmacological Reports</i> , 2008, 60, 532-41.	3.3	39
157	Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3 β ,7 β -dihydroxy-12-OXO-5 β -cholanate, in healthy and diabetic rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2007, 32, 7-12.	1.6	29
158	Probiotics Applications in Autoimmune Diseases. , 0, , .		6
159	Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System. <i>Journal of Endocrinology and Diabetes Mellitus</i> , 0, , .	0.4	4
160	Au -- NHC complexes with thiocarboxylate ligands: Synthesis, structure, stability, thiol exchange and <i>in vitro</i> anticancer activity. <i>Applied Organometallic Chemistry</i> , 0, , .	3.5	6